StonvexLoading…
StonvexStonvexStonvexCore line items from TMHC's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $8.12B | $8.17B | $7.42B | $8.22B |
Operating Income | Not available | Not available | Not available | Not available |
Net Income | $782.50M | $883.31M | $768.93M | $1.05B |
EPS (Diluted) | $7.77 | $8.27 | $6.98 | $9.06 |
Total Assets | $9.84B | $9.30B | $8.67B | $8.47B |
Total Liabilities | $3.53B | $3.42B | $3.34B | $3.82B |
Cash & Equivalents | $850.04M | $487.15M | $798.57M | $724.49M |
Free Cash Flow OCF − CapEx | $776.97M | $173.75M | $772.74M | $1.08B |
Shares Outstanding | 96.54M | 102.24M | 106.92M | 108.00M |